MRNA logo

Moderna

MRNA · What the business does, what can go wrong, and how options sellers approach it

What it does

Moderna is a biotechnology company built around messenger RNA (mRNA) technology. mRNA carries instructions that tell the body's cells how to make a specific protein. Moderna designs these instructions to train the immune system or to produce a protein a patient needs.

Its best-known products are vaccines for COVID-19 and other respiratory viruses. It also runs research programs in cancer, rare genetic diseases and other areas.

How it makes money

Revenue comes mainly from selling vaccines to governments, health systems and pharmacies. Sales can be seasonal and tied to vaccination campaigns. The company may also earn money from partnerships, licensing and government contracts. Since it spends heavily on research and clinical trials, profits have varied a lot.

Why investors own it

Investors are usually betting that mRNA can become a broad platform, not a one-product story. If the same core technology can be adapted to many diseases, new programs could be developed faster than with some traditional methods. Some also value the potential in individualized cancer treatments and the company's manufacturing know-how.

What can go wrong

  • Demand for COVID-19 vaccines can fall and swing with public health policy.
  • Clinical trials can fail, and regulators can delay or deny approvals.
  • Competition from large pharmaceutical companies and other vaccine makers is intense.
  • Pricing, reimbursement and vaccine recommendations can change.
  • Heavy research spending can drain cash if revenue disappoints.
  • Public attitudes toward vaccines can affect sales.

What to watch

  • Regulatory decisions and trial results for pipeline candidates
  • Vaccine sales and seasonal demand trends
  • Government vaccine recommendations and purchasing policy
  • Operating expenses and cash runway
  • Progress on cancer and rare disease programs
  • Competing vaccine launches

Options income angle

Options on MRNA are generally actively traded, with many strikes and expirations, so liquidity is typically decent. Implied volatility tends to rise ahead of trial readouts, regulatory decisions, earnings reports and vaccine policy news, and it can drop sharply once the news is out.

A caution for anyone selling premium: biotech stocks can gap sharply on a single announcement. A short call can cap gains in a big rally, and a short put can lead to a large loss if the shares fall far below the strike. High premiums often reflect that risk.

What the latest 10-K says

A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 20, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The filing in brief

Moderna's 2025 revenue fell again as COVID vaccine demand shrank, but sharp cost cuts narrowed the net loss. The company reports approximately $8.1 billion in cash, cash equivalents and investments at year-end, which includes a $600 million draw on a new term loan. Management expects product sales to return to growth in 2026. COVID and RSV vaccines were the company's only commercial products at year-end, so its outlook depends on launching new ones.

How the business did

  • Total revenue was $1.9 billion in 2025, compared with $3.2 billion in 2024 and $6.8 billion in 2023. Net product sales decreased by $1.3 billion, or 42%, mainly on lower COVID vaccine volumes in all regions.
  • U.S. net product sales were $1,165 million, versus $1,726 million in 2024. Europe fell to $50 million from $573 million, partly because government advance purchase agreements from the prior year were completed. RSV vaccine sales were $8 million.
  • Net loss was $2.8 billion versus $3.6 billion in 2024, and loss per share was $(7.26) versus $(9.28). Research and development expenses fell by $1.4 billion, or 31%, and selling, general and administrative expenses fell by $156 million, or 13%.
  • Cost of sales included inventory write-downs of $291 million and unutilized manufacturing capacity and wind-down costs of $93 million. Management tied these to COVID demand forecasts that missed and to terminated manufacturing contracts.
  • Net cash used in operations was $1.9 billion. Cash, cash equivalents and investments decreased by $1.4 billion, or 15%, partly offset by $578 million of net proceeds from the credit facility.

Risks specific to this company

  • Shrinking COVID demand and shifting U.S. policy. Changes at the FDA, CDC and the vaccine advisory committee (ACIP) may affect demand. The RSV vaccine has also struggled, partly because advisory recommendations were more limited than anticipated.
  • Locked out of much of Europe. The company says it has been excluded from selling COVID vaccines in many European markets because of a competitor's contract with the European Commission. That contract does not lapse until year-end 2026.
  • Ongoing losses and secured debt. The company has lost money in every year except 2022 and 2021. Its credit agreement with lenders led by Ares Capital Corporation is secured, and breaking its covenants could let lenders demand immediate repayment. The company says it was in compliance as of December 31, 2025.
  • Drug pricing pressure. A May 12, 2025 executive order asks drugmakers to align U.S. prices with those in comparable nations ("most-favored-nation" pricing). The filing says it remains to be seen how this will apply to Moderna's products.
  • Manufacturing and supply. The company relies on single-source suppliers and has entered take-or-pay purchase commitments, which are purchases it must pay for even if demand falls. Contract manufacturers have had lot failures that led to COVID vaccine recalls in the past.
  • Liability protection and lawsuits. At filing, the COVID vaccine had U.S. liability protection under the PREP Act. If the government revokes or changes it, product liability exposure could rise significantly. Class action and derivative suits over RSV vaccine statements were filed in 2024.

What management is watching

  • 2026 sales. Management expects product sales to return to growth, helped by a full year of long-term government partnerships and continued U.S. uptake of the mNEXSPIKE COVID vaccine.
  • Flu vaccine decision. The FDA accepted the amended application for the mRNA-1010 flu vaccine and set a PDUFA goal date (the FDA's target decision date) of August 5, 2026. For the flu and COVID combination vaccine, mRNA-1083, the company was awaiting FDA guidance on refiling.
  • Spending. Management anticipates a modest reduction in research and development expenses in 2026. It expects selling, general and administrative expenses and cost of sales to stay relatively consistent with 2025.
  • Pipeline priorities. Management named intismeran autogene, a cancer therapy developed with Merck, and its norovirus vaccine as late-stage programs it will keep advancing. A January 2026 collaboration with Recordati covers the rare disease candidate mRNA-3927.
  • Funding and manufacturing. Management believes existing cash and available borrowings will fund operations for at least 12 months from the issuance of the financial statements. Drug product manufacturing is being onshored to Norwood, Massachusetts, with completion targeted for the first half of 2027.

Follow MRNA in Kortex

The Kortex app shows MRNA's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.